

BAUS Muscle Invasive Bladder Cancer at Transurethral REsection of Bladder (MITRE) Audit  
National Summary Results – August 2022

	National Figures	
<b>Demographic</b>		
<b>Number of complete submissions from units</b>	641 (72 exclusions)	
<b>Median follow up</b>	38 months (IQR: 37-39) (Full range: 35-41)	
<b>Median age</b>	76 (IQR: 69-83) (Full range: 35-104)	
<b>Male / Female ratio</b>	M: 403 F: 166	70.8% 29.2%
<b>Smoking</b>		
Smoker	94	16.5%
Previous smoker	145	25.5%
Non smoker	137	24.1%
Unknown	193	33.9%
<b>Source of referral</b>		
2ww	347	61%
Emergency	89	15.6%
Other speciality	53	9.3%
Already under urology	80	14.1%
<b>Method of diagnosis</b>		
First TURBT	461	81%
Re-resection	49	8.6%
Surveillance	59	10.4%
<b>Stage at diagnosis</b>		
N0 M0	418	73.5%
N1 M0	44	7.7%
N2 M0	15	2.6%
N3 M0	4	0.7%
M1	88	15.5%
<b>Safety domain – pathway</b>		
<b>Time from referral to TURBT (median)</b>	41 days (IQR: 26-73) (Full range: 0-8424)	
<b>MDT outcome no mention of neoadjuvant chemotherapy / reason for not considering in NOMO disease</b>	207/418	49.5%
<b>Number of patients undergoing cystectomy</b>	119	20.9%
<b>Time from referral to cystectomy (median)</b>	143 days (IQR: 89-205) (Full range: 2-5614)	
<b>Neoadjuvant chemotherapy prior to cystectomy</b>	46/119	38.7%
<b>Number of patients undergoing radiotherapy</b>	162	28.5%
<b>Neoadjuvant chemotherapy prior to radiotherapy</b>	58/162	35.8%
<b>Patients undergoing no treatment</b>	288	50.6%
<b>Efficacy domain – outcomes</b>		
<b>Of those undergoing cystectomy</b>		
Alive at audit follow-up	60	50.4%
Alive with metastases	13	10.9%
Dead	46	38.7%
<b>Of those undergoing radiotherapy</b>		
Alive at audit follow-up	68	42.0%
Alive with metastases	15	9.3%
Dead	79	48.8%
<b>Of those undergoing no treatment</b>		
Alive at audit follow-up	27	9.4%
Alive with metastases	11	3.8%
Dead	250	86.8%

## Information for Trusts

### Quality Accounts & Reporting

- This audit is included in the Quality Accounts List 2022/23
- The national summary results were presented at the BAUS 2022 Annual Scientific Meeting in June 2022 and uploaded onto the BAUS website in August 2022
- Individual unit feedback on key metrics important to bladder cancer patients and their pathways was sent to the Clinical Lead for Urology in all participating units (see below) to allow benchmarking against the national data and to drive quality improvement
- The audit collected data on the management and outcomes of patients diagnosed with muscle invasive bladder at transurethral resection of the bladder and variations in pathways and treatments received in the UK including receipt of neoadjuvant chemotherapy and timings to treatment

### Data Collection

- Data was collected on all patients with a diagnosis of Muscle Invasive Bladder Cancer made at a transurethral resection of bladder tumour (TURBT) performed between 1 January 2019 and 31 March 2019 inclusive
- Data submission took place between 1 March 2022 and 30 April 2022 inclusive
- Data collection was retrospective to allow entry of follow-up data
- Anonymised unit level data only was collected
- 641 complete datasets were captured from 98 hospitals, including Wales, Scotland and Northern Ireland

### Re-auditing

- A template for this audit and guidance on how to repeat it in your Trust, is available by **email from Louisa Hermans** (BAUS Programme Manager)

## Contributing Hospitals

Addenbrooke's Hospital, Cambridge  
Aintree University Hospital, Liverpool  
Airedale Hospital  
Alexandra Hospital, Redditch  
Altnagelvin Area Hospital, Londonderry  
Ashford Hospital, Middlesex  
Basildon University Hospital, Essex  
Basingstoke & North Hampshire Hospital  
Belfast City Hospital  
Cheltenham General Hospital  
Chesterfield Royal Hospital  
Countess of Chester Hospital  
Craigavon Area Hospital, Portadown  
Croydon University Hospital, Surrey  
Darent Valley Hospital, Kent  
Derriford Hospital, Plymouth  
Eastbourne District General Hospital  
Epsom General Hospital, Surrey  
Freeman Hospital, Newcastle  
Furness General Hospital, Barrow-in-Furness  
George Eliot Hospital, Nuneaton  
Glangwili General Hospital, Carmarthen  
Good Hope Hospital, Sutton Coldfield  
Guy's and Thomas's Hospital, London  
Harrogate District Hospital  
Heartlands Hospital, Birmingham  
Hereford County Hospital  
James Paget University Hospital, Great Yarmouth  
Kent & Canterbury Hospital  
King's Mill Hospital, Nottinghamshire  
Kingston Hospital, London  
Leicester General Hospital  
Lincoln County Hospital  
Lister Hospital, Stevenage  
Maidstone Hospital  
Manchester Royal Infirmary  
Musgrove Park Hospital, Taunton  
New Cross Hospital, Wolverhampton  
Norfolk and Norwich University Hospital  
North Devon District Hospital, Barnstaple  
North Middlesex Hospital, London  
Northampton General Hospital  
Northwick Park Hospital, Harrow

BAUS Muscle Invasive Bladder Cancer at Transurethral REsection of Bladder (MITRE) Audit  
National Summary Results – August 2022

Nottingham City Hospital  
Peterborough City Hospital  
Pilgrim Hospital, Boston  
Pinderfields General Hospital, Wakefield  
Princess Royal University Hospital, Orpington  
Queen Alexandra Hospital, Portsmouth  
Queen Elizabeth Hospital, Birmingham  
Queen Elizabeth Hospital, King's Lynn  
Queen's Hospital, Burton-on-Trent  
Raigmore Hospital, Inverness  
Royal Albert Edward Infirmary, Wigan  
Royal Berkshire Hospital  
Royal Blackburn Hospital  
Royal Bolton Hospital  
Royal Cornwall Hospital, Truro  
Royal Derby Hospital  
Royal Devon & Exeter Hospital  
Royal Free Hospital, London  
Royal Hampshire County Hospital, Winchester  
Royal Lancaster Infirmary  
Royal Liverpool & Broadgreen University Hospitals  
Royal Oldham Hospital  
Royal Preston Hospital  
Royal Shrewsbury Hospital  
Royal Stoke University Hospitals  
Royal Sussex County Hospital, Brighton  
Royal United Hospital, Bath  
Salford Royal Hospital  
Salisbury District Hospital  
Scunthorpe General Hospital  
South Eastern Health Trust, Northern Ireland  
Southampton General Hospital  
Southend Hospital  
Southmead Hospital, Bristol  
Southport and Formby District General Hospital  
St James University Hospital, Leeds  
St Richard's Hospital, Chichester  
Stepping Hill Hospital, Stockport  
The Great Western Hospital, Swindon  
The James Cook University Hospital, Middlesbrough  
Torbay Hospital, Torquay  
University College Hospital, London  
University Hospital of North Tees  
University Hospital of Wales, Cardiff  
University Hospital, Coventry

BAUS Muscle Invasive Bladder Cancer at Transurethral REsection of Bladder (MITRE) Audit  
National Summary Results – August 2022

Walsall Manor Hospital

Warrington District General Hospital

Watford General Hospital

West Suffolk Hospital

Western General Hospital, Edinburgh

Wexham Park Hospital, Slough

Whiston Hospital

Whittington Hospital, London

Worthing Hospital

York Hospital